Promethazine use and QT prolongation risk during treatment with a shortened all-oral regimen for MDR/RR-TB. (PubMed, JAC Antimicrob Resist) - Oct 8, 2026 - "Shortened all-oral regimens for multidrug- or rifampicin-resistant tuberculosis (MDR/RR-TB) combine multiple QTc prolonging agents, including bedaquiline and delamanid, which act partly through hERG potassium channel binding...We conducted secondary analyses from a prospective observational cohort study of patients ≥15 years in Lesotho who received a 9- to 12-month all-oral regimen (bedaquiline, linezolid, levofloxacin, clofazimine, delamanid) for pulmonary MDR/RR-TB...We conducted comparator analyses with time-varying exposure to metoclopramide, ondansetron, and episodes of nausea, dizziness, and vomiting...Promethazine use was associated with increased risk of clinically relevant QTc prolongation within a QTc-burdened all-oral MDR/RR-TB regimen. These findings provide preliminary evidence that clinicians may consider when selecting anti-emetics as part of MDR/RR-TB therapy with a shortened all-oral regimen and highlight the importance of evaluating adjunctive..."
Journal • Human Immunodeficiency Virus • Infectious Disease • Pulmonary Disease • Respiratory Diseases • Tuberculosis
|
|
Allison LaHood; Carole D Mitnick; Edmund Q L Shen; Elna Osso; Kunda Kwabisha Mikanda; Kwonjune Justin Seung; Lawrence Oyewusi; Letizia Trevisi; Llang Maama; Matthew Romo; Meseret Tamirat; Michael L Rich; Molly F Franke; Sebakeng Phate; Stephane Mpinda
|